Search

Your search keyword '"Nakamura, Hideki"' showing total 2,115 results

Search Constraints

Start Over You searched for: Author "Nakamura, Hideki" Remove constraint Author: "Nakamura, Hideki"
2,115 results on '"Nakamura, Hideki"'

Search Results

204. Additional file 1 of Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan

205. Additional file 1 of Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis

206. sj-pdf-1-imr-10.1177_03000605211002083 - Supplemental material for Tocilizumab has no direct effect on cell lines infected with human T-cell leukemia virus type 1

207. Comparison of salivary gland MRI and ultrasonography findings among patients with Sjögren's syndrome over a wide age range.

208. Combination of MRI-detected bone marrow oedema with 2010 rheumatoid arthritis classification criteria improves the diagnostic probability of early rheumatoid arthritis

214. Clinical, serologic and magnetic resonance imaging of 3 cases of inflammatory myopathy with abundant macrophages in the Japanese population

215. Significant improvement in MRI-proven bone edema is associated with protection from structural damage in very early RA patients managed using the tight control approach

216. Validation of different sets of criteria for the diagnosis of Sjögren’s syndrome in Japanese patients

223. Magnetic resonance imaging (MRI) detection of synovitis and bone lesions of the wrists and finger joints in early-stage rheumatoid arthritis: comparison of the accuracy of plain MRI-based findings and gadolinium-diethylenetriamine pentaacetic acid-enhanced MRI-based findings

224. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome

226. Real-World Comparative Effectiveness and Safety of Tofacitinib and Baricitinib in Patients with Rheumatoid Arthritis

230. Treatment discontinuation in patients with very early rheumatoid arthritis in sustained simplified disease activity index remission after synthetic disease-modifying anti-rheumatic drug administration

231. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors

237. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline

239. Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor

240. Contribution of an adenine to guanine single nucleotide polymorphism of the matrix metalloproteinase-13 (MMP-13) −77 promoter region to the production of anticyclic citrullinated peptide antibodies in patients with HLA-DRB1*shared epitope-negative rheumatoid arthritis

Catalog

Books, media, physical & digital resources